Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance

Maicol Mancini 1,*, Quentin-Dominique Thomas 1,†, Sylvia Bourdel 1,‡, Laura Papon 1, Emilie Bousquet 1, Prisca Jalta 1, Silvia La Monica 2, Camille Travert 1, Roberta Alfieri 2, Xavier Quantin 1, Marta Cañamero 3,† and Antonio Maraver 1,*

Abstract: Despite the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) to treat advanced lung cancer harboring EGFR-activating mutations, the prognosis remains unfavorable because of intrinsic and/or acquired resistance. We generated a new state-of-the-art mouse strain harboring the human EGFR(T790M/L858R) oncogene and MET overexpression (EGFR/MET strain) that mimics the MET amplification occurring in one out of five patients with EGFR-mutated lung cancer. Moreover, EGFR/MET-driven lung tumors were resistant only to EGFR TKI. We found that survival was reduced in EGFR/MET mice compared with mice harboring EGFR(T790M/L858R) (EGFR strain). However, EGFR/MET-driven lung tumors were resistant to osimertinib, recapitulating the phenotype observed in patients. Conversely, as also observed in patients, the crizotinib (anti-MET TKI) and osimertinib combination improved survival and reduced tumor burden in EGFR/MET mice, further validating the model’s value for preclinical studies.

Keywords: lung cancer; EGFR; MET; TKI; preclinical mouse models
1. Introduction

EGFR-activating mutations, such as exon 19 deletion or the L858R mutation in exon 21, occur in 10–15% of patients with non-small cell lung cancer. For these patients, targeted therapy is proposed as first-line treatment because it provides a clear advantage compared to standard chemotherapy. First-generation (e.g., gefitinib and erlotinib) and second-generation (e.g., afatinib) tyrosine kinase inhibitors (TKIs) can be used as first-line treatment in these patients, but resistance invariably appears in all patients. In 50% to 65% of them, this occurs through acquisition of the so-called gatekeeper EGFR mutation T790M [1]. Interestingly, third-generation TKIs (i.e., osimertinib) led to important tumor regression in EGFR<sup>T790M</sup> lung cancer following relapse after first-generation TKIs [2]. Moreover, in the FLAURA phase 3 clinical trial, progression-free survival and overall survival were longer with osimertinib than with first-generation TKIs and, therefore, in many countries, osimertinib has become the first-line standard of care for patients with EGFR-mutated non-small cell lung cancer (NSCLC) [3]. Nevertheless, relapse also occurs in osimertinib-treated patients. Several studies showed that in patients with EGFR-mutated lung cancer, osimertinib resistance can be promoted by MET amplification in around 20% of cases [4]. A very recent phase 1b clinical trial showed a therapeutic benefit of the combination of osimertinib and the MET inhibitor savolitinib in this patient subtype [5]. Although these results are very encouraging, the therapeutic effectiveness of osimertinib needs to be increased because the effect of the MET inhibitor–TKI combination in this particular trial remained modest. Importantly, the implementation of new treatments might be delayed due to the lack of good preclinical tools.

Here, we describe the generation and characterization of a new mouse model obtained by combining doxycycline-inducible expression in the lung of the human EGFR<sup>T790M/L858R</sup> oncogene, which promotes the development of EGFR-driven lung cancer when expressed alone [6], and wild type human MET, using a transgenic mouse model that promotes liver carcinoma when a liver-specific promoter is used [7]. Our new model fully recapitulates the treatment response observed in patients with EGFR-mutated lung cancer who relapse after osimertinib. We also found that MET overexpression reduced the levels of phosphorylated EGFR (pEGFR, i.e., the activated form) and total EGFR, and this effect was prevented by MET amplification in around 20% of cases [4]. A very recent phase 1b clinical trial showed a therapeutic benefit of the combination of osimertinib and the MET inhibitor savolitinib in this patient subtype [5]. Although these results are very encouraging, the therapeutic effectiveness of osimertinib needs to be increased because the effect of the MET inhibitor–TKI combination in this particular trial remained modest. Importantly, the implementation of new treatments might be delayed due to the lack of good preclinical tools.

The present study offers a rationale to propose EGFR and MET inhibitors always in combination to patients with lung cancer harboring EGFR mutations and MET amplification. Our new compound mouse strain will pave the way to in vivo preclinical studies to test new therapeutic options in this specific genetic context with important clinical implications.

2. Results

2.1. MET Overexpression Decreases Survival of Mice Harboring EGFR-Driven Lung Adenocarcinoma

To develop a mouse model that could recapitulate osimertinib resistance caused by MET amplification in patients with EGFR-mutated lung cancer, we took advantage of a mouse strain in which liver carcinoma develops upon induction of human WT MET expression in the liver [7]. This mouse model relies on the same doxycycline-inducible genetic system used in the EGFR<sup>T790M/L858R</sup> transgenic mouse strain that we previously crossed with the lung-specific CCSP-rtTA strain (EGFR<sup>T790M/L858R/rtTA</sup>, EGFR mice hereafter) and in which EGFR-driven lung adenocarcinoma appears upon doxycycline exposure [6]. We crossed the MET and EGFR strains to generate the EGFR<sup>T790M/L858R/MET/rtTA</sup> compound mouse (EGFR/MET mice hereafter) (Figure 1A). Upon doxycycline exposure, survival was reduced in EGFR/MET mice compared with EGFR mice (median survival: 18.2 weeks for EGFR and 6.5 weeks for EGFR/MET mice) (Figure 1B). Death was related to breathing
problems and we observed tumors only in lungs. Analysis of a subset of moribund mice showed a similar tumor burden in lungs from both strains (Supplemental Figure S1A). However, and in accordance with the survival curves, EGFR/MET mice reached this stage earlier than EGFR mice (Supplemental Figure S1B). Histological analysis of lung samples from these mice showed the same lung adenocarcinoma features in both genotypes (Supplemental Figure S1C): solid pattern with high mitotic activity, nuclear atypia, and presence of cytoplasmic vacuoles in some cases. Moreover, in EGFR/MET-driven tumor samples, there were also extensive areas of alveolar hyperplasia and pneumonia, with alveoli filled with macrophages and plasma cells surrounding the adenocarcinoma mass or within edematous areas in the tumor (Supplemental Figure S1C). The reasons for such differences in infiltration will require further investigations, but they probably contributed to the reduced survival of EGFR/MET mice. Finally, the percentage of adenocarcinomas relative to the adenomas at death was lower in EGFR/MET than EGFR mice (Figure 1C), a feature probably related to their shorter survival with less time to allow tumors to become full-blown carcinomas.

Figure 1. MET overexpression decreases survival of mice harboring EGFR-driven lung adenocarcinoma. (A) Cartoon depicting the strategy to generate EGFR/MET mice (top) and to activate the lung-specific expression of the two transgenes upon exposure to doxycycline diet (bottom). (B) Kaplan–Meier plot showing the survival rate of EGFR (n = 14) and EGFR/MET (n = 12) mice after doxycycline induction; **** p ≤ 0.0001 (Mantel–Cox test). (C) Percentage of adenocarcinomas vs. adenomas in each genotype. Values correspond to the mean ± SEM; * p ≤ 0.05 (unpaired t-test). EGFR (n = 6) and EGFR/MET (n = 5). (D) Immunoblotting of the indicated proteins in lung tumors from EGFR and EGFR/MET mice.
We also analyzed the expression of different proteins implicated in EGFR-driven lung adenocarcinoma. As expected, EGFR/MET-driven tumors showed strong MET expression and activation (phosphorylated MET, pMET) compared with EGFR-driven tumors (Figure 1D). Conversely, phosphorylated ERK (pERK) levels were lower, while phosphorylated AKT (pAKT) levels were similar between genotypes. Intriguingly, EGFR and pEGFR levels were strongly reduced in EGFR/MET-driven tumors compared with EGFR-driven tumors (Figure 1D), suggesting that MET overexpression negatively regulates EGFR.

2.2. MET Overexpression Decreases EGFR Activity

To determine whether the MET-induced EGFR inhibition observed in lung tumors from EGFR/MET mice was clinically relevant, we performed a correlation analysis of pEGFR and pMET expression in a TCGA cohort of patients with lung adenocarcinoma [9]. We found a negative correlation between pEGFR and pMET expression, suggesting that active MET could also inhibit EGFR activity in patients (Figure 2A) as it could also suggest that the two populations, i.e., high pEGFR and high pMET, are mutually exclusive.

To investigate the underlying mechanism, we used the human lung adenocarcinoma H1975 cell line that, as in our mouse models, also harbor the EGFR T790M/L858R mutations. We transduced this cell line with lentivirus particles harboring a newly generated doxycycline-inducible MET expression plasmid, obtaining an H1975 cell line in which pMET and total MET were strongly expressed upon exposure to doxycycline (Figure 2B). Of note, pEGFR and total EGFR levels were decreased upon induction of MET expression (Figure 2B), thus recapitulating our in vivo findings (Figure 1D). We also confirmed this observation in another lung adenocarcinoma cell line with inducible MET expression that we generated starting from the KRAS-mutated A549 cell line (Supplemental Figure S2A).

Altogether, these findings demonstrated that MET expression decreases EGFR activity. In order to understand this phenotype, we looked for negative regulators of EGFR and, among the different ones, we focused on MIG6 because (i) it is upregulated by EGFR and in turn modulates EGFR function [8] and (ii) because MIG6 has been reported to also be upregulated by the MET ligand HGF [10]; hence we hypothesized that MIG6 could be affected by MET overexpression (amplification or ectopic expression). Importantly, MIG6 regulates EGFR at the phosphorylation level [10], and the negative correlation we observed in patients was between pEGFR and pMET (Figure 2A). Therefore, we first analyzed, in the same patient cohort, the correlation between EGFR and the gene encoding for MIG6 (ERRFI1) expression, and found a positive correlation (Figure 2C, left panel). ERRFI1 was also positively correlated with MET expression, with a higher Pearson correlation coefficient than for the ERRFI1–EGFR correlation (Figure 2C, right panel). Then, we analyzed for MIG6 gene mRNA expression in inducible MET-expressing H1975 and A549 cells and found increased mRNA levels upon incubation with doxycycline (Supplemental Figure S2B). In accordance with the increased mRNA levels, MIG6 protein levels were also higher in both cell lines upon MET expression (Supplemental Figure S2C). In order to firmly link MIG6 to the MET-induced EGFR and pEGFR decreased expression, we performed MIG6 loss of function experiments in H1975 and A549. Interestingly, when MIG6 levels were reduced in A549 cells, the levels of EGFR and pEGFR upon MET overexpression were restored when compared to the steady state control, and the same phenotype also occurred in H1975, albeit to a lesser extent (Figure 2D).

Altogether, these data indicated that MET overexpression in human cells increased the expression of MIG6, a negative regulator of EGFR, which in turn diminished pEGFR and EGFR levels.
Figure 2. MET expression decreases EGFR activity. (A) Correlation analyses of pMET and pEGFR expression status (Z-scores) in 360 patients from the Lung Adenocarcinoma (TCGA, PanCancer Atlas) dataset. Data were analyzed by Pearson coefficient analysis ($r = -0.2037$). Linear regression (black line) and 95% confidence intervals (dashed red lines) are also indicated. (B) Immunoblotting of the indicated proteins in H1975 cells infected with lentiviral particles harboring the doxycycline-inducible MET construct (METOX) or empty vector (e.v.). Cells were incubated (+) or not (−) with 1 µg/mL of doxycycline for 48 h. This is a representative example of an experiment performed twice. (C) Correlation analyses for EGFR vs. ERRFI1 (MIG6 gene) and MET vs. ERRFI1 (MIG6 gene) mRNA expression (Z-scores) in 510 patients from the Lung Adenocarcinoma (TCGA, PanCancer Atlas) dataset. Z-scores were analyzed by Pearson coefficient analysis ($r = 0.190$ and $r = 0.314$, respectively). Linear regression (black line) and 95% confidence intervals (dashed red lines) are also indicated. (D) Immunoblotting of the indicated proteins in H1975 and A549 cells infected with lentiviral particles harboring the doxycycline-inducible MET construct (METOX) and transfected with non-targeting siRNA (siNT) or siRNA targeting MIG6 (siMIG6). Cells were incubated (+) or not (−) with 1 µg/mL of doxycycline for 48 h. This is a representative example of an experiment performed twice.
2.3. EGFR/MET-Driven Tumors Are Resistant to Osimertinib

An important feature in patients with EGFR-mutated lung cancer and MET amplification is that they are resistant to osimertinib [4]. To validate our new preclinical model, we treated EGFR and EGFR/MET mice harboring tumors with this TKI. As survival was shorter in EGFR/MET than EGFR mice (Figure 1B), we treated mice with doxycycline for 9 (EGFR) or 5 weeks (EGFR/MET). The EGFR/MET group started doxycycline 4 weeks later than the EGFR group to then initiate the TKI treatment at the same time (see Supplemental Figure S3A for the experiment design). After induction, mice were randomized into two groups to be treated with vehicle or osimertinib for 4 weeks. As before, all vehicle-treated EGFR/MET mice reached the end point (breathing distress and suffocation) before the treatment ended, while only one vehicle-treated EGFR mouse reached this point during this period. All other EGFR mice (vehicle or osimertinib) were euthanized after the 4 weeks of treatment. Analysis of tumor burden showed that in EGFR mice, osimertinib efficiently controlled EGFR tumor growth (Figure 3A,B), with a three-fold decrease in the percentage of tumor cells (52% in vehicle-treated and 17% in osimertinib-treated mice) (Figure 3B). Conversely, in EGFR/MET mice, osimertinib’s effect was mild and non-significant (60% of tumor cells in vehicle-treated and 48% in osimertinib-treated mice) (Figure 3B). This demonstrated that EGFR/MET tumors are resistant to osimertinib, mimicking what is observed in EGFR-mutated lung cancer patients with MET amplification.

![Figure 3](image-url)

**Figure 3.** EGFR/MET-driven tumors are resistant to osimertinib. (A) Hematoxylin and eosin staining of whole lungs from EGFR mice treated with vehicle (n = 5) or osimertinib (n = 4) and EGFR/MET mice treated with vehicle (n = 5) or osimertinib (n = 5) for 4 weeks. Scale bar, 5 mm. (B) Tumor burden from same samples as described in (A). Values are the mean ± SEM, ***p ≤ 0.001, ****p ≤ 0.0001 (one-way ANOVA followed by Tukey post hoc test). (C) Immunoblotting of the indicated proteins in lung tumors from EGFR and EGFR/MET mice treated with vehicle or osimertinib. (D) Immunoblotting of the indicated proteins in lungs tumors from EGFR and EGFR/MET mice treated as in (C).

Protein expression analysis in these mice highlighted several features. First, and in accordance with our previous data, pEGFR and total EGFR levels were higher in EGFR-driven than EGFR/MET-driven tumors. Then, osimertinib treatment decreased pEGFR level in all tumors, regardless of the genotype (Figure 3C). Osimertinib treatment also decreased pERK and pAKT levels in EGFR-driven but not in EGFR/MET-driven tumors, where pAKT levels even increased (Figure 3C), further confirming that EGFR/MET tumors are resistant to osimertinib. Moreover, osimertinib strongly reduced MIG6 protein...
and mRNA levels in EGFR-driven but not in EGFR/MET-driven tumors (Figure 3D and Supplemental Figure S3B), probably because MET maintained MIG6 expression. Of note, MIG6 expression was higher in EGFR/MET-driven than EGFR-driven tumors, indicating that, as it happens in human cells, MET increased MIG6 expression.

We conclude that our new mouse strain mimics the osimertinib resistance observed in patients with EGFR-mutated and MET-amplified lung cancer.

2.4. EGFR/MET-Driven Tumors Are Sensitive to the Osimertinib and Crizotinib Combination

We sought to inhibit both pathways at the same time and hence we treated EGFR/MET mice with the combination of osimertinib and crizotinib, a clinically relevant MET TKI [11,12]. We exposed EGFR/MET mice to doxycycline for 5 weeks as before (Supplemental Figure S3A), and then randomized them into four groups: vehicle, single treatment (osimertinib or crizotinib) and their combination. We treated mice until all mice reached the end point, and then collected samples for analysis. After 6 weeks of treatment, only animals in the combination group were still alive and we euthanized them to analyze all mice at the same time. One mouse in the combination treatment group died due to a wound caused by another mouse that could not be healed and was censored for the survival analysis.

The osimertinib/crizotinib combination increased survival compared with all other groups (Figure 4A). Similarly, tumor burden was significantly lower in the combination group (23%) compared with vehicle- (55%) and crizotinib-treated mice (53%) (p < 0.01). We observed a similar trend compared with osimertinib-treated mice (43%) (p = 0.06) (Figure 4B and Supplemental Figure S4A).

Protein expression analysis revealed that crizotinib treatment increased pEGFR expression, confirming the negative effect of MET expression on EGFR (Figure 4C). In this treatment group, pMET was strongly reduced, as expected, and also pAKT and pERK. Conversely, pERK was decreased compared with vehicle, possibly due to the longer treatment period (6 weeks vs. 4 weeks in the experiment of Figure 3C). The combination very strongly reduced pMET, pEGFR, pAKT and pERK levels, further confirming that this treatment is the most effective against EGFR/MET-driven tumors. Finally, osimertinib and crizotinib alone did not decrease MIG6 protein or mRNA levels, suggesting that EGFR and MET might compensate each other when only one is inhibited. Indeed, MIG6 levels (protein and mRNA) were decreased only when both pathways were inhibited with the drug combination (Figure 4D and Supplemental Figure S4B).

Finally, we report the case of a 69-year-old woman treated by us in our local hospital (Montpellier Cancer Institute, ICM, Montpellier, France) (Supplemental Figure S4C). She was diagnosed with NSCLC harboring an exon 19 deletion in EGFR. She was treated with afatinib (second-generation EGFR TKI) for 23 months. Pleural progression led to a second line of chemotherapy (platinum-based therapy combined with pemetrexed) for four cycles, resulting in renal failure and hence treatment stopped. Osimertinib was proposed as third-line treatment and initiated 33 months after first diagnosis, concomitant with observation of brain metastasis. Pulmonary tumor biopsy was also performed at this time and we found a MET amplification (MET/CEP7 ratio > 4.08). Osimertinib treatment promoted a complete cerebral response but, conversely, there was progression in abdominal lymph nodes and adrenal glands less than 3 months after treatment initiation. Since we detected a MET amplification, the patient was treated with a combination of osimertinib and crizotinib without any obvious side effect. This combination led to a durable response with an excellent extra-cerebral control (Figure 4E) while also keeping the brain metastasis under control. This clinical case further validates the EGFR/MET mice as a preclinical model mimicking the human disease.
Figure 4. EGFR/MET-driven tumors are sensitive to the osimertinib and crizotinib combination. (A) Kaplan–Meier plot showing the survival rate of EGFR/MET mice treated with vehicle, crizotinib and/or osimertinib (n = 4 mice/group) for 6 weeks. The x axis shows the time since tumor induction by doxycycline; * p ≤ 0.05 (Mantel–Cox test) (B) Tumor burden from the mice described in (A) (n = 4 animals per treatment group). Data are the mean ± SEM; ** p ≤ 0.01 (one-way ANOVA followed by Tukey post hoc test). (C) Immunoblotting of the indicated proteins in lung protein extracts from the same mice described in (A). (D) Immunoblotting of the indicated proteins in lung protein extracts from the same mice described in (A). (E) CT scan of a patient presenting EGFR del19 mutation and MET amplification upon relapse after osimertinib single treatment (CT1) and 3 months after osimertinib and crizotinib treatment started (CT2). Magnification of the tumoral area is presented and highlighted in red.

3. Discussion

Here, we described a new mouse strain in which human WT MET and the EGFR<sup>T790M/L858R</sup> oncogenes are concomitantly expressed in the lung. These mice develop lung tumors and die due to breathing problems earlier than mice that only express EGFR<sup>T790M/L858R</sup>. This is despite the fact that in EGFR/MET mice, the number of full-blown adenocarcinomas was smaller, possibly because of a lack of time to acquire further mutations to promote disease progression. On the contrary, the tumor burden at the time of death by suffocation was
very similar among both strains, hence we suggest that an accelerated tumor growth in EGFR/MET mice could be at the origin of the accelerated death compared to EGFR mice.

An interesting feature in EGFR/MET-driven tumors, compared with EGFR-driven tumors, was the concomitant strong reduction in pEGFR and total EGFR. Remarkably, their levels were increased after treatment with crizotinib alone, demonstrating that the inhibitory effect is promoted by MET activity. We are not aware of any previous published study on this effect. On the other hand, we found some studies showing the same finding in their figures, but without explicitly mentioning it because they were focused on other aspects, for instance, in one study using the human HCC877 cell line with spontaneous MET amplification [13]. Furthermore, the group of Pasi Jänne reported at AACR 2019 three patient-derived models with mutant EGFR and MET amplification and those models had less EGFR expression than their controls [14]. Here, we also unveiled MIG6 as one important player in the MET-induced decreased levels of EGFR. At this stage, we cannot rule out that, besides MIG6, other EGFR negative regulators could also play a role in the MET-induced inhibition of EGFR. In any case, we think that this is a very important finding because single treatment with anti-MET TKIs in patients with EGFR-mutated and MET-amplified lung cancer will restore EGFR activity. Moreover, we also found that osimertinib alone did not affect pERK activity and increased pAKT expression in EGFR/MET-driven tumors, which could provide pro-survival signals to the cancer cells even in the absence of pEGFR. Therefore, our preclinical data strongly suggest that the combination of osimertinib and a MET inhibitor should be always proposed to this subset of patients as for instance in the clinical case reported in Figure 4E. Our work is in accordance with previous clinical studies showing a poor response to crizotinib alone in patients with EGFR-mutated lung cancer with MET amplification [15].

Our preclinical model mimics the therapeutic responses to osimertinib and the combination of osimertinib and crizotinib, a MET TKI. Indeed, in EGFR/MET mice, this combination increased survival, decreased tumor burden and reduced the expression levels of all the tested key proteins implicated in lung adenocarcinoma (pEGFR, pMET, pAKT and pERK), compared with the single treatments or vehicle. Moreover, we observed a decrease in total MET and total EGFR levels. This is in accordance with previous work showing that when targeted therapy is effective in EGFR-mutated cancer cell lines, EGFR is downregulated [16], and further supports the effectiveness of the crizotinib and osimertinib combination in EGFR/MET-driven tumors. Finally, this combination was effective in one EGFR-mutated patient with MET amplification at our local hospital, Montpellier Cancer Institute, and fits with a very recent clinical trial showing that the combination of osimertinib and a MET inhibitor (savolitinib) has a therapeutic effect in patients with EGFR-mutated and MET-amplified lung cancer following relapse after osimertinib [5], further validating the EGFR/MET mouse as a preclinical model mimicking the human disease.

In summary, our new preclinical mouse model will help the lung cancer community to develop and test in vivo new therapeutic options for patients with EGFR-mutated lung cancer who relapse after osimertinib-based therapy due to the appearance of MET amplification, for instance, the bispecific antibody amivantamab against EGFR and MET [17].

4. Material and Methods
4.1. Mice and Genotyping

Tet-on-EGFR<sup>T790M/L858R</sup>, Tet-on-MET and CCSP-rtTA mice were described previously [18–20]. DNA was isolated using the REDExtract-N-Amp Tissue PCR Kit (Sigma) according to the manufacturer’s protocol. The rtTA, EGFR and MET transgenes were detected by PCR from DNA tails as described previously [18–20]. Transgenes were induced by using doxycycline-supplemented food (1 mg/kg) purchased from SAFE.

Animal procedures were performed according to protocols approved by the French National Committee of Animal Care.
4.2. Cell Culture, Western Blotting and Transfection Reagents

The H1975 and A549 lung cancer cell lines were from the American Type Tissue Culture Collection (ATCC) and were maintained in RPMI 1640 supplemented with 10% fetal bovine serum and antibiotics.

Western blotting was performed as previously described [21], with antibodies against pEGFR (#2234), EGFR (#4267), pMET (#3077), MET (#198), pAKT (#4060), AKT (#4691), pERK (#4370), ERK (#9102) and MIG6 (#2440) from Cell Signaling Technology, tubulin (#4026) from Sigma, HSC70 (sc-7298) and MIG6 (sc-137154) from Santa Cruz. Secondary antibodies were horseradish peroxidase-linked anti-rabbit (#7074) and anti-mouse IgG from Cell Signaling Technology. Tubulin served as a loading control for human samples and HSC70 for murine samples.

The siRNA non-targeting control (siNT, #D-001206-14) and that against MIG6 (siMIG6, #L-017016-001) from Dharmacon were used to transfect cells at 20 nM with Dharmafect1 reagent following the manufacturer’s instructions.

The full uncropped WB are available at Supplemental Figure S5.

4.3. Generation of Cell Lines with Inducible MET Overexpression

MET cDNA was purchased from Addgene (#37560) and inserted into the pENTRY vector (Invitrogen) by PCR using the following forward and reverse primers: 5′-CACCATGAAGGCCCCCGCTGT-3′ and 5′-CTATGATGTCTCCCAGAAGGAGGC-3′. MET cDNA was then transferred into a pCLX vector using the Gateway system to generate the pCLX-METOX plasmid for lentiviral particle production in HEK 293T cells, following the manufacturer’s guidelines (Sigma, St. Louis, MO, USA). Target cells were infected with METOX-encoding lentiviruses supplemented with polybrene (8 mg/mL) and cultured in the presence of puromycin (2 mg/mL) for 4 days.

4.4. Treatments in Mice

Crizotinib (#AB-M1765) from AbMole and osimertinib (#T2490) from TargetMol were resuspended in vehicle (0.5% (w/v) methylcellulose, 0.2% Tween 80 (w/v)) and administered (50 mg/kg/day and 2.5 mg/kg/day, respectively) by oral gavage 5 days per week.

4.5. qPCR

For mRNA expression, total RNA was isolated using the RNeasy Mini Kit (Quiagen, Hilden, Germany). Complementary DNA was synthesized using SuperScriptIII (Invitrogen, Waltham, MA, USA) and qPCR was performed using the following primer pairs:

- Human ERRFI1 forward: 5′-TGTGAACGGGGTTCTAGGC-3′ and reverse: 5′-TGGTCAAGCACATAGCTGAGA-3′
- Mouse Errfi1 forward: 5′-TGGCCTACAATCTGAACTCCC-3′ and reverse: 5′-GACCACTCTGCAAAGAAGTG-3′
- Human ACTB forward: 5′-CTGTCTGGCGGCCACCTACC-3′ and reverse: 5′-GCAAACACAGCTCTAC-3′
- Mouse Actb forward: 5′-ATGCCCTCCCCCTACGCCATC-3′ and reverse: 5′-CACGCACGATTCCCTCTCA-3′

qPCR analyses were performed using SYBR Green (Applied Biosystems, Waltham, MA, USA) and the specific primers described above. Real-time PCR was carried out on a LightCycler 480 II (Roche, Basel, Switzerland). Reactions were run in triplicate. Expression data were normalized to the geometric mean of the housekeeping gene ACTB (Actb for mouse samples) to control the variability in expression levels and analyzed using the 2-DDCT method.

4.6. Analysis of Publicly Available Datasets

To analyze the relationship between pEGFR and pMET expression and between EGFR, MET and ERRFI1 mRNA expression in lung adenocarcinomas, data were extracted from TCGA [9] through www.cbioportal.org (we downloaded the data on 26 April 2021).
Specifically, on the home page of the website, the RPPA data as Z-score expression in the Lung Adenocarcinoma (TCGA, PanCancer Atlas) database from 360 patients were downloaded for pEGFR and pMET analysis, and the EGFR vs. ERRFI1 and MET vs. ERRFI1 mRNA expression Z-scores relative to all samples (log RNA Seq V2 RSEM) in the Lung Adenocarcinoma (TCGA, PanCancer Atlas) database from 510 patients were downloaded. The correlations between Z-scores were then analyzed by Pearson correlation and plotted using Prism GraphPad. Linear regression with 95% confidence intervals was also calculated and plotted using Prism GraphPad.

4.7. Histopathology and Immunohistochemistry

Lung lobes were fixed, embedded in paraffin and stained with hematoxylin and eosin (HE). To calculate tumor burden, both tumor area and total lung area were measured using ImageJ software and presented as percentages. For pathological analysis of HE-stained tissue sections, classical cytological and architectural features (e.g., invasion and high mitotic rate) were examined by our expert pathologist (M.C.), who also counted the number of adenomas and adenocarcinomas in each sample to show the percentage of adenocarcinomas.

4.8. Statistical Analysis

Unless otherwise specified, data are presented as mean ± standard error of the mean (SEM). One-way analysis of variance (ANOVA) was carried out to compare ERRFI1 mRNA expression levels (Figures 3D and 4D), and tumor burden among groups of mice receiving different treatments (Figures 3B and 4B). An unpaired t-test was used to compare two different groups, as shown in Supplemental Figure S1A,B, Figure 2D,E and Supplemental Figure S2B. The Kaplan–Meier survival curves were compared with the Mantel–Cox test. All statistical analyses were performed using Prism GraphPad software.

4.9. Clinical Case

Camille Travert and Xavier Quantin, authors of the study, followed this patient at Montpellier Cancer Institute (ICM) in Montpellier. The patient’s data presented were collected after her oral consent. We used months of treatment instead of real dates to maintain confidentiality and the data presented are strictly limited to this study.

5. Conclusions

We have developed a new preclinical mouse model that will help the lung cancer community to develop and test in vivo novel therapeutic options for patients with EGFR-mutated lung cancer who relapse after osimertinib therapy due to the appearance of MET amplification.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13143441/s1, Figure S1: (A) Tumor burden in hematoxylin & eosin-stained lung samples from EGFR (n = 6) and EGFR/MET (n = 6) mice (see Figure 1C). Data are the mean ± SEM; n.s., not significant (unpaired t-test). (B) Survival time after MET and EGFR transgene induction with doxycycline (same mice as in A). Data are the mean ± SEM; *** p ≤ 0.001 (unpaired t-test). (C) Four examples of adenocarcinoma in EGFR (mice 1 and 3) and EGFR/MET (mice 2 and 4) mice. All were solid adenocarcinomas with high proliferation rate, as indicated by several mitotic figures in metaphase. In mouse 2, the tumor was surrounded by a dense infiltrate with macrophages and plasma cells. In mouse 4, the presence of edema with macrophages could be observed. Scale bar, 100 µm. Figure S2: (A) Immunoblotting of the indicated proteins in A549 cells infected with lentiviral particles harboring the doxycycline-inducible MET construct (METOX) or empty vector (e.v.). Cells were incubated (+) or not (−) with 1 µg/mL of doxycycline for 48 h. This is a representative example of an experiment performed twice. (B) ERRFI1 mRNA levels in A549 and H1975 cells infected with lentiviral particles harboring the doxycycline inducible MET construct (METOX, n = 3). Cells were treated or not with 1 µg/mL of doxycycline for 48 h. Values are the mean ± SD; * p ≤ 0.05, ** p ≤ 0.01 (unpaired t-test). (C) Immunoblotting of the indicated proteins in A549 and H1975 cells treated as
in A. This is a representative example of an experiment performed three times. Figure S3: (A) The cartoon depicts the experimental setting of Figure 3. (B) Errfi1 mRNA expression levels in lung tumors from EGFR and EGFR/MET mice treated with vehicle or osimertinib (n = 4 tumors/group). Values are the mean ± SEM; * p ≤ 0.05, *** p ≤ 0.001 (one-way ANOVA followed by the Tukey post-hoc test). Figure S4: (A) Examples of hematoxylin and eosin staining of whole lungs from EGFR/MET mice treated as described in Figure 4A. Scale bar, 5 mm. (B) Errfi1 mRNA expression levels in lungs from EGFR/MET mice treated as described in Figure 4A (n = 4 animals per treatment group). Values are mean ± SEM; * p ≤ 0.05 (one-way ANOVA followed by the Tukey post-hoc test). (C) The cartoon depicts the clinical observations and treatments of the case report referring to Figure 4E. Figure S5: Uncropped Western blot images.

Author Contributions: Conceptualization, M.M. and A.M.; methodology, M.M.; formal analysis, M.M., Q.-D.T., S.B., P.J., L.P., E.B., S.L.M., C.T., M.C. and A.M.; investigation, M.M., Q.-D.T., S.B., P.J., L.P., E.B., S.L.M. and C.T.; writing—original draft preparation, M.M. and A.M.; writing—review and editing, Q.-D.T., C.T., X.Q. and M.C.; supervision, R.A., X.Q., M.C. and A.M.; project administration, A.M.; funding acquisition, A.M. All authors have read and agreed to the published version of the manuscript.

Funding: M.M. was supported by contracts from Fondation ARC, Institut National du Cancer (INCa_9257) and Occitane Region/FEDER funds (LR0014155). Work in A.M.’s lab is supported by the Fondation ARC (PJA 20131200405), the European Commission (CIG631431), the Institute de Cancer de Montpellier Fondation, the Occitane Region/FEDER funds (LR0014155) and the Institut National du Cancer (INCa_9257 and SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553).

Institutional Review Board Statement: Animal procedures were performed according to protocols approved by the French National Committee of Animal Care, that depends on “Ministere de l’enseignement supérieur, de la recherche et de l’innovation”. In particular, we used protocol number 13357.

Informed Consent Statement: Informed consent was obtained from the patient involved in the study.

Data Availability Statement: The clinical data presented in this study are available on request from the corresponding author. The data are not publicly available due to patient protection.

Acknowledgments: We thank David Santamaría, Olivier Calvayrac, Julien Mazières, Zoulika Kherrouche, Alexis Cortot, Daniel Herranz, Eric Fabrizzio and Hélène Tourriere for helpful discussion and critical reading of the manuscript. Elisabetta Andermarcher professionally edited the manuscript. We thank Alexandre Djiane for his kind gift of the pCLX vector. We thank the IRCM animal facility members for their outstanding work.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Tan, C.S.; Gilligan, D.; Pacey, S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. *Lancet Oncol.* 2015, 16, e447–e459. [CrossRef]
2. Mok, T.S.; Wu, Y.L.; Ahn, M.J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.; et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N. Engl. J. Med.* 2017, 376, 629–640. [CrossRef]
3. Soria, J.C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chevaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2018, 378, 113–125. [CrossRef]
4. Piper-Vallillo, A.J.; Sequist, L.V.; Piotrowska, Z. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. *J. Clin. Oncol.* 2020. [CrossRef]
5. Sequist, L.V.; Han, J.Y.; Ahn, M.J.; Cho, B.C.; Yu, H.; Kim, S.W.; Yang, J.C.; Lee, J.S.; Su, W.C.; Kowalski, D.; et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study. *Lancet Oncol.* 2020, 21, 373–386. [CrossRef]
6. Bousquet Mur, E.; Bernardo, S.; Papon, L.; Mancini, M.; Fabbriozio, E.; Goussard, M.; Ferrer, I.; Giry, A.; Quantin, X.; Pujol, J.L.; et al. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. *J. Clin. Investig.* 2020, 130, 612–624. [CrossRef]
7. Yuneva, M.O.; Fan, T.W.; Allen, T.D.; Higashi, R.M.; Ferraris, D.V.; Tsukamoto, T.; Mates, J.M.; Alonso, F.J.; Wang, C.; Seo, Y.; et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. *Cell Metab.* 2012, 15, 157–170. [CrossRef]

8. Anastasi, S.; Lamberti, D.; Alema, S.; Segatto, O. Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics. *Semin. Cell Dev. Biol.* 2016, 50, 115–124. [CrossRef]

9. Hoadley, K.A.; Yau, C.; Hinoue, T.; Wolf, D.M.; Lazar, A.J.; Drill, E.; Shen, R.; Taylor, A.M.; Cherniack, A.D.; Thorsson, V.; et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell* 2018, 173, 291–304. [CrossRef]

10. Pante, G.; Thompson, J.; Lamballe, F.; Iwata, T.; Ferby, I.; Barr, F.A.; Davies, A.M.; Maina, F.; Klein, R. Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth. *J. Cell Biol.* 2005, 171, 337–348. [CrossRef]

11. Landi, L.; Chiari, R.; Tiseo, M.; D’Inca, F.; Dazzi, C.; Chella, A.; Delmonte, A.; Bonanno, L.; Giannarelli, D.; Cortinovis, D.L.; et al. Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. *Clin. Cancer Res.* 2019, 25, 7312–7319. [CrossRef]

12. Wang, W.; Wang, H.; Lu, P.; Yu, Z.; Xu, C.; Zhuang, W.; Song, Z. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: A multicenter retrospective study. *J. Transl. Med.* 2019, 17, 52. [CrossRef] [PubMed]

13. Shi, P.; Oh, Y.T.; Zhang, G.; Yao, W.; Yue, P.; Li, Y.; Kanteti, R.; Riehm, J.; Salgia, R.; Owonikoko, T.K.; et al. MET gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer models. *Cancer Lett.* 2016, 380, 494–504. [CrossRef] [PubMed]

14. Marrocco, I.; Romaniello, D.; Vaknin, I.; Drago-Garcia, D.; Oren, R.; Uribe, M.L.; Nataraj, B.N.; Ghosh, S.; Eilam, R.; Salame, T.M.; et al. Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models. *EMBO Mol. Med.* 2021, 13, e13144. [CrossRef] [PubMed]

15. Xiong, H.; Mancini, M.; Gobert, M.; Shen, S.; Furtado, G.C.; Lira, S.A.; Parkhurst, C.N.; Garambois, V.; Brengues, M.; Tadokoro, C.E.; et al. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. *Theranostics* 2021, 11, 1594–1608. [CrossRef] [PubMed]